This is the authors' abstract. We don't add key points for this paper.
Chimeric Antigen Receptor (CAR)-modified T cells, or CAR-T cell therapy, is emerging as a promising new strategy for immunotherapy, and by modifying T cells in vitro to add a CAR that specifically recognizes tumor antigens, CAR-T cell immunotherapy improves tumor-specific killing. This immune cell therapy has the advantages of good targeting and killing power, and it enables effective activation and proliferation of T cells independent of MHC molecules, which is a very effective new strategy for immune killing. In this paper, we will introduce the composition of CAR, the basic principles of CAR-T cell immunotherapy and the preparation aspects of CAR-T cells, and highlight an overview of the use of CAR-T cell immunotherapy in various tumor treatments in recent years.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: